Core Viewpoint - Fudan Zhangjiang (01349) experienced a nearly 3% decline in stock price following the announcement of its mid-year results for 2025, reflecting a decrease in revenue and profit [1] Financial Performance - The company reported revenue of approximately 390 million yuan, representing a year-on-year decrease of 4.42% [1] - Shareholder profit attributable to the company was 5.715 million yuan, a significant year-on-year decline of 91.89% [1] - Earnings per share were reported at 0.0055 yuan [1] Reasons for Profit Decline - The decline in profit was primarily attributed to an increase in research and development expenses compared to the same period last year [1] - The previous year's results included compensation and penalties related to the termination of cooperation with the promotional service provider, Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. [1]